Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation
Executive Summary
Sanofi-Aventis' revised R&D structure will include the push down to smaller, more independent structures that has characterized other big pharma companies' efforts to improve their R&D activity
You may also be interested in...
Life Without Plavix: Sanofi Highlights Next Generation Drugs
Sanofi will lose exclusivity for Plavix, Avapro and Eloxatin in 2012, driving what it expects will be a 12% to 15% EPS decline, but management is counting on a new wave of drugs – and the addition of Genzyme – to return to growth.
Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
Sanofi Aventis reported second quarter net sales up 6.5 percent at constant exchange rates, despite the early impact of generic competition in Europe on the heart drug Plavix (clopidogrel), anti-hypertensive Avapro (irbesartan), and cancer drug Eloxatin (oxaliplatin)
Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
Sanofi Aventis reported second quarter net sales up 6.5 percent at constant exchange rates, despite the early impact of generic competition in Europe on the heart drug Plavix (clopidogrel), anti-hypertensive Avapro (irbesartan), and cancer drug Eloxatin (oxaliplatin)